Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.63 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.59 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726960 | 1.00 | CRBN (0.73) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL27305814 | 1.00 | CRBN (0.73) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL29614623 | 1.00 | CRBN (0.73) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL30930592 | 0.93 | CRBN (0.63) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL30984806 | 0.90 | CRBN (0.67) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL19100445 | 0.90 | CRBN (0.61) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL21855270 | 0.90 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL22034379 | 0.90 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL29439987 | 0.90 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL19792875 | 0.88 | CRBN (0.57) | CRBNDDB1IKZF2CSNK1A1SALL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | claimed |
| CN-113662941-A | Antiproliferative compounds and pharmaceutical compositions and uses thereof | 细胞基因公司 | 2021-11-19 | — | — | CN | claimed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | claimed |
| CN-122071478-A | Compound for targeted degradation of GLI1 protein and medicinal application thereof | 苏州大学 | 2026-05-22 | — | — | CN | disclosed |
| CN-122070278-A | Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof | 标新生物医药科技(上海)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-116457344-B | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20150374678-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CELGENE CORPORATION | 2015-12-31 | — | — | US | disclosed |
| WO-2015200795-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON OTHER E3 UBIQUITIN LIGASES | CELGENE CORPORATION (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-2291365-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2057143-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374678-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885IKZF2 1029/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885IKZF2 3972/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885IKZF2 3972/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CRBN 1468/4885DDB1 629/4885IKZF2 1313/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | CRBN 2904/4885DDB1 363/4885IKZF2 3518/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | CRBN 1/4885DDB1 399/4885IKZF2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.